Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash ConcernsSeeking Alpha · Oct 13, 2026
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 5, 2026
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
Cabaletta Bio to Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 1, 2026
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire · Aug 13, 2026Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.37 | -$0.34 | Beat |
| May 14, 2026 | -$0.41 | -$0.39 | Beat |
| Mar 23, 2026 | -$0.45 | -$0.40 | Beat |
| Nov 10, 2025 | -$0.49 | -$0.44 | Beat |
| Aug 7, 2025 | -$0.71 | -$0.73 | Miss |
| May 15, 2025 | -$0.67 | -$0.71 | Miss |